Stock Analysis, Dividends, Split History

FINL / Finish Line, Inc. (THE) financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price13.51
Volume5,145,900.00
Market Cap ($M)547.38
Enterprise Value ($M)453.99
Book Value ($M)450.99
Book Value / Share11.13
Price / Book1.21
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Stock Shares Outstanding 40,370,000
Common Shares Outstanding 40,516,631
Scoring Models
Piotroski F-Score5.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.03
Return on Assets (ROA)0.02
Return on Equity (ROE)0.03
Balance Sheet (mrq) ($M)
Assets675.03
Liabilities224.04
Quick Ratio0.82
Current Ratio2.71
Income Statement (mra) ($M)
Sales Revenue Net1,838,956,000.00
Disposal Group Including Discontinued Operation Revenue0.00
Operating Income8.92
Net Income14.41
Earnings Per Share Diluted0.35
Earnings Per Share Basic0.35
Cash Flow Statement (mra) ($M)
Cash From Operations77.74
Cash from Investing-51.96
Cash from Financing-51.96
Identifiers and Descriptors
CUSIP317923100
Central Index Key (CIK)886137
Related CUSIPS
317923950 317923900 031792310
Industry Groups
SIC 5661 - Shoe Stores

Split History

Stock splits are used by Finish Line, Inc. (THE) to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon
FINL: The Finish Line Analysis and Research Report

2018-02-22 - Asif

The Company is a premium retailer of athletic shoes, apparel, and accessories for men, women, and kids, throughout the United States, Guam, and Puerto Rico, through multiple operating segments. Headquartered in Indianapolis, Finish Line runs approximately 950 branded locations in U.S. malls and shops inside Macy’s department stores. Finish Line employs more than 14,000 associates who connect customers to sneaker culture through style and sport Brick and mortar comparable sales are the change in net sales year over year for the reporting periods presented from Finish Line stores open longer than one year, beginning in the thirteenth month of a store’s operation. Expanded stores are excluded from the brick and mortar comparable sales calculation until the thirteenth month following the re-opening of the store and temporarily closed stores are excluded during the months that the store is closed. Brick and mortar comparable sales do not include sales from shops within department stores....

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

Related News Stories

Nvidia Posts Sluggish Guidance, Retail Sector Sees Mixed Results

2018-08-17 zacks
On today’s episode of the Zacks Friday Finish Line, Associate Stock Strategist Ryan McQueeney and Editor Maddy Johnson recap this week’s global macroeconomic headlines and highlight the latest earnings results from Nvidia (NVDA - Free Report) , Walmart (WMT - Free Report) , and the U.S. department store giants. (9-0)

Disney Earnings, Amazon-Walmart War Intensifies, & Is Musk Unhinged?

2018-08-11 zacks
On today’s episode of the Zacks Friday Finish Line, Associate Stock Strategist Ryan McQueeney and Editor Maddy Johnson investigate the latest moves in the Amazon-Walmart war, highlight the ill-fated Tribune-Sinclair merger, and recap Disney’s new earnings report. Later, the hosts have some fun breaking down Elon Musk’s surprising tweets about taking Tesla private. (5-0)

Mixed FANG Earnings, Oil Stocks Stutter, & Grubhub Goes Shopping

2018-07-27 zacks
On today’s episode of the Zacks Friday Finish Line, Associate Stock Strategist Ryan McQueeney and Editor Maddy Johnson take on this week’s biggest stories, including Grubhub’s shiny new acquisition, Spotify’s impressive user growth, and mixed reactions to earnings announcements from FANG stocks and oil giants. (12-1)

In Defense Of Skechers

2018-07-25 seekingalpha
Skechers (SKX) shares fell last week after the company missed earnings for the second straight quarter. Reported EPS of $0.29 fell well below analyst estimates and guidance provided the prior quarter. In addition, domestic wholesale sales were down 7% year/year, a concerning development. (16-0)

Comcast-Disney News, Google's EU Fine, & Earnings from IBM and Microsoft

2018-07-20 zacks
On today’s episode of the Zacks Friday Finish Line, Associate Stock Strategist Ryan McQueeney and Editor Maddy Johnson take on this week’s biggest stories, including the latest twist in the ongoing battle between Comcast and Disney to buy Fox assets, Google’s new legal headache in Europe, and earnings report from the likes of IBM and Microsoft. (7-0)

Silicon Investor Message Boards

This table lists all message boards related to FINL / Finish Line, Inc. (THE) on message board site Silicon Investor.

FINLINE Technologies Ltd. (FIN-CDNX) FINLINE Technologies Ltd. (FIN-CDNX) FINLINE Technologies Ltd. (FIN-CDNX) FINL (Finish Line) FINL (Finish Line) FINL (Finish Line)
J Doe #13 C. Finley Portfolio J Doe #13 C. Finley Portfolio J Doe #13 C. Finley Portfolio
CUSIP: 317923100